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SUMMARY
Cortistatin A (CA) is a highly selective inhibitor of the Mediator kinases CDK8 and CDK19. 
Using CA, we now report a large-scale identification of Mediator kinase substrates in human cells 
(HCT116). We identified over 16,000 quantified phosphosites including 78 high-confidence 
Mediator kinase targets within 64 proteins, including DNA-binding transcription factors and 
proteins associated with chromatin, DNA repair, and RNA polymerase II. Although RNA-Seq data 
correlated with Mediator kinase targets, the effects of CA on gene expression were limited and 
distinct from CDK8 or CDK19 knockdown. Quantitative proteome analyses, tracking around 
7,000 proteins across six time points (0 – 24h), revealed that CA selectively affected pathways 
implicated in inflammation, growth, and metabolic regulation. Contrary to expectations, increased 
turnover of Mediator kinase targets was not generally observed. Collectively, these data support 
Mediator kinases as regulators of chromatin and RNA polymerase II activity and suggest their 
roles extend beyond transcription to metabolism and DNA repair.
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INTRODUCTION
An important first step in understanding the cellular function of kinases is to identify the 
substrates that they modify. This first step has remained a persistent challenge, in part 
because of the difficulties in the development of highly potent and selective kinase 
inhibitors. The human CDK8 kinase exists in a 600 kDa complex known as the CDK8 
module, which consists of four proteins (CDK8, CCNC, MED12, MED13). The CDK8 
module associates with regulatory loci on a genome-wide scale (Kagey et al., 2010; Pelish et 
al., 2015), and global targeting of the CDK8 module appears to reflect its association with 
Mediator (Allen and Taatjes, 2015). CDK19, a paralog of CDK8, emerged in vertebrates and 
has high sequence similarity to CDK8, including nearly identical cyclin binding and kinase 
domains. Comparatively little is known about CDK19; however, it appears to assemble into 
an analogous CDK19 module in human cells (Daniels et al., 2013).
Based upon their association with Mediator—a global regulator of RNA polymerase II (pol 
II) transcription—CDK8 or CDK19 may broadly impact gene expression patterns; however, 
physical knockdown of CDK8 or CDK19 protein levels had relatively modest effects in 
HCT116 cells, with 2-fold or greater changes in expression of several hundred genes 
(Donner et al., 2010; Galbraith et al., 2013). Whereas knockdown studies do not address the 
role of the kinase activity per se, these data suggested limited roles for the Mediator kinases 
in transcriptional regulation. In agreement, gene expression analyses with the CDK8 
ortholog in yeast, Srb10 (Holstege et al., 1998), revealed that about 3% of genes were 
regulated by Srb10 kinase activity. Similarly, limited effects on yeast transcription were 
observed in vitro and in vivo upon selective inhibition of Srb10 (CDK8) kinase activity 
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using an analog-sensitive mutant (Liu et al., 2004). Most genes affected by kinase-inactive 
mutant Srb10 (CDK8) were involved in cellular response to nutrient stress (Holstege et al., 
1998).
The biological roles of human CDK8 and CDK19 remain poorly understood, in part, 
because a more comprehensive identification of their substrates or the genes specifically 
regulated by their activities has been lacking. Our recent studies with the natural product, 
cortistatin A (CA), showed that CA is a potent and highly selective inhibitor of the Mediator 
kinases CDK8 and CDK19 (Pelish et al., 2015). CA binds the CDK8–CCNC dimer with 
sub-nanomolar affinity (Kd = 195 pM) and two distinct kinome profiling assays, which 
collectively probed approximately 400 kinases, ultimately confirmed only CDK8 and 
CDK19 as targets of CA, even with analyses completed at 100-times the measured IC50 for 
CDK8 (Pelish et al., 2015). Given these and other data showing the unusual selectivity of 
CA, we could begin to probe the cellular function and targets of CDK8 and CDK19.
Here, we report the large-scale identification of Mediator kinase (CDK8 and CDK19) 
substrates in human cells, using SILAC-based phosphoproteomics. We couple these results 
with global analysis of gene expression changes (RNA-Seq) that result from targeted 
inhibition of Mediator kinase activity. Furthermore, we assess potential Mediator kinase 
effects on protein turnover using quantitative proteomic analyses across 6 time points 
spanning 24 hours of Mediator kinase inhibition. HCT116 cells were chosen for this study 
for several reasons. First, although CA potently inhibits Mediator kinase activity in HCT116 
cells (Pelish et al., 2015), proliferation is not affected. This eliminated potential confounding 
effects, such as induction of cell cycle arrest or death, which could have complicated our 
analyses. Second, CDK8 is a colon cancer oncogene that was uncovered, in part, by an 
shRNA screen in HCT116 cells (Firestein et al., 2008). Third, published gene expression 
data exist in HCT116 cells with stable CDK8 or CDK19 knockdown (Donner et al., 2010; 
Galbraith et al., 2013), which allowed us to directly compare and de-couple the effects of 
subunit knockdown vs. targeted inhibition of kinase activity.
RESULTS
Quantitative phosphoproteomics in HCT116 cells ± CA
To identify cellular CDK8 and CDK19 substrates, we used stable isotope labeling of amino 
acids in cell culture (SILAC) coupled with a phosphoproteomics workflow. Experiments 
were completed in HCT116 cells supplemented with heavy (Arg10, Lys8) or light (Arg0, 
Lys0) amino acids. Control (DMSO) and CA-treated cells were harvested and mixed 1:1 
based on total protein content (CA structure shown in Fig. 1A). Phosphopeptides were 
isolated using titanium enrichment, followed by offline electrostatic repulsion hydrophilic 
interaction chromatography (ERLIC) with LC-MS/MS for phosphosite identification (Fig. 
1B). We collected 24 fractions during ERLIC fractionation, with an average phosphopeptide 
enrichment of over 50% in biological triplicate experiments (Fig. 1C). In total, over 16,000 
heavy-light (H/L) phosphosite ratios were quantified (Table S1) and over 12,000 were 
present in at least two biological replicates (Fig. 1D).
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The majority of phosphosites were unaffected by CA treatment, clustering around zero in a 
log2 plot of H/L SILAC ratios across replicate experiments (Fig. 1D). This result indicated 
good reproducibility and provided further validation of CA specificity. Many decreased 
phosphosites were highly correlated across replicates (highlighted green in Fig. 1D); in 
addition, we identified a smaller number of phosphosites that increased upon CA treatment 
(highlighted peach in Fig. 1D; Table S2). Representative mass spectra for SILAC pairs 
shown in Figure 1E and 1F are from experiments in which either light (E) or heavy (F) cells 
were treated with CA. For two of three replicates, the heavy population of cells was CA 
treated, whereas in one replicate light cells were CA treated, representing a label swap. For 
data analysis purposes, a reciprocal of the H/L ratio was calculated for the label swap 
experiment, such that decreased H/L ratios could be evaluated across all biological 
replicates.
Mediator kinase substrates are largely transcription-associated proteins
The phosphoproteomics workflow in Fig. 1B identified novel phosphosites whose intensities 
decreased significantly with CA treatment (Fig. 2A). We identified 78 phosphosites, 
represented in 64 proteins, that we designated as high confidence based upon 1) their 
quantification in at least two of three biological replicates, 2) a reproducible mean H/L ratio 
across replicates, and 3) a significant decrease in H/L ratio with CA treatment as determined 
by an empirical Bayes analysis (Margolin et al., 2009; Ritchie et al., 2015). These high-
confidence phosphosites are summarized in Table 1 and Figure 2A, and all quantified 
phosphosites are shown in Table S1. To ensure that a reduced H/L ratio did not result simply 
from a change in protein level, we completed a quantitative proteome analysis in parallel 
with phosphoproteomics. Importantly, very few high confidence phosphosites exhibited any 
change at the protein level with one hour of CA treatment (Table S2). Those that did change 
somewhat were FOXC1, MAML1, KDM3A, and ATF2, although some of these changes 
were not consistent across deep proteome replicates, and most of the phosphosite changes 
remained significant even after accounting for small changes in protein level. Although 
phosphosites not designated as high confidence sites could represent bona-fide Mediator 
kinase substrates (e.g. those that are quantified in only one biological replicate) we will only 
discuss targets designated as high confidence based on the criteria above.
To determine whether a H/L ratio for a phosphosite changed significantly with CA treatment 
across replicates, we employed an empirical Bayes statistical approach using the limma 
software package (Ritchie et al., 2015). An empirical Bayesian framework allowed for the 
calculation of adjusted p-values for each phosphosite (Fig. 2B). This approach can account 
for experiment-specific differences, which is advantageous compared to more arbitrary 
approaches, such as a universal fold-change cutoff (Margolin et al., 2009). We found that 
more phosphosite ratios decreased than increased upon CA treatment, as expected with 
targeted kinase inhibition for a short amount of time. This is shown by a higher number of 
data points on the left side of the volcano plot compared to the right side, using an adjusted 
p-value cutoff of 0.1 (Fig. 2B; see also Supplemental Note).
We used iceLOGO (Colaert et al., 2009) to determine statistically enriched motifs within the 
identified Mediator kinase substrates. We found that the majority of the phosphosites 
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contained an S/T-P motif (Fig. S1A). Additionally, a proline at the −2 and −1 positions 
relative to the phosphorylation site was overrepresented. These data support the notion that 
many CDK8 phosphorylation sites occur within PX(S/T)P motifs as previously suggested 
(Alarcon et al., 2009; Bancerek et al., 2013). Serine was more frequently phosphorylated 
than threonine (Fig. S1A) and we did not see evidence for overrepresentation of basic 
residues at positions C-terminal to the phosphosite, as observed with other CDK motifs 
(Ubersax and Ferrell, 2007).
Because few substrates for human CDK8/19 have been identified, the analysis uncovered 
many phosphosite targets (Table 1). Many targets are DNA-binding transcription factors 
(TFs), chromatin regulators, or other known regulators of pol II activity (Fig. 2A, Fig. S1B), 
consistent with the established role of CDK8 in transcription. Additional substrates, 
including proteins implicated in DNA replication and repair (BRCA1, MDC1) and 
ubiquitination (HUWE1, CUL4B) suggest biological roles for Mediator kinases beyond 
transcription. A known CDK8 substrate, STAT1 S727 (Bancerek et al., 2013), was identified 
as a high confidence target, and other novel phosphosites reside in proteins that interact with 
CDK8-Mediator and/or the CDK8 module, including AFF4, MAML1, and Mediator 
subunits (Fig. 2A, Table 1). AFF4 is a core component of the super-elongation complex 
(SEC; (Luo et al., 2012)), which co-purifies with CDK8-Mediator (Ebmeier and Taatjes, 
2010), and MAML1 is a Notch pathway co-activator that recruits CDK8 to Notch-dependent 
genes where it phosphorylates the Notch ICD (Fryer et al., 2004).
We submitted the 64 CDK8/19 substrate proteins to the STRING protein-protein interaction 
database (Szklarczyk et al., 2015) and found that six Mediator complex subunits, three 
subunits of the TIP60/NuA4 complex (EPC2, DMAP1, MRGBP), and two subunits of the 
NuRD complex (CHD3 and CHD4) were represented (high confidence score, ≥ 0.7; Fig. 
S1C). The TIP60/NuA4 and NuRD complexes are multi-subunit assemblies that possess 
multiple enzymatic activities, including nucleosome remodeling, acetyltransferase, and 
deacetylase activities. Additionally, this analysis identified a network of interacting proteins 
involved in DNA damage repair (Fig. S1C), as well as an interaction between XRN2 and 
SETX. Taken together, these data suggest that Mediator kinases regulate multiple and 
diverse cellular processes, potentially via several distinct multi-subunit assemblies.
Validation of selected Mediator kinase substrates
To further validate the CDK8/19 substrates identified with SILAC-based 
phosphoproteomics, we performedin vitro kinase assays, western blots, and MS 
experiments. We selected proteins representing different classes of substrates (Fig. 2A) for 
further evaluation. The DNA-binding TF STAT1, a previously identified CDK8 kinase 
substrate (Bancerek et al., 2013), was probed by western blot in IFN-γ induced HCT116 
cells (Fig. 3A). This experiment confirmed STAT1 S727 as a Mediator kinase substrate in 
HCT116 cells, and also showed CA-dependent inhibition at low nM concentrations, as 
reported previously (Pelish et al., 2015).
Among the chromatin modification and regulation substrates, we examined SIRT1, in part 
because an antibody against the phosphorylated SIRT1 T530 site was commercially 
available. When HCT116 cells were treated with CA, we noted a decrease in SIRT1 T530 
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phosphorylation (Fig. 3B and 3C). Total SIRT1 levels were unaffected by CA treatment, and 
levels of the CDK8 module subunits CDK8, CCNC, and MED12 were not changed by 
treatment with the compound (Fig. 3B). The approximately 50% reduction in phospho-
SIRT1 did not change with increasing CA concentration, indicative of CA selectivity (Pelish 
et al., 2015). Although other kinases, such as CDK1 and JNK, are known to phosphorylate 
this site (Sasaki et al., 2008), treatment with inhibitors of CDK1 (RO-3306) and JNK family 
kinases (SP600125) did not seem to impact SIRT1 T530 phosphorylation; in fact, we were 
unable to completely reduce SIRT1 phospho-T530 detection, even when treating with all 
three inhibitors (Fig. S2). In vitro kinase assays with purified CDK8 module and SIRT1 
confirmed CDK8-dependent SIRT1 T530 phosphorylation by western blot (Fig. 3D).
We next tested two different substrates, RIF1 and TP53BP1, linked to DNA replication and 
repair. Because these proteins are very large (each over 200 kDa), we expressed GST-tagged 
fragments (ca. 100 residues) surrounding the phosphosite. As shown in Figure 3E, the 
CDK8 module phosphorylated these substrates, whereas point mutations (S to A) at the 
identified phosphorylation site(s) greatly reduced substrate phosphorylation, supporting 
these sites as CDK8 module targets in vitro (Fig. 3E).
We also confirmed phosphorylation sites in MED12 and MED13 using in vitro kinase assays 
using the recombinant CDK8 module (containing CDK8, CCNC MED12, MED13) purified 
from insect cells. Incubation of the CDK8 module with ATP and subsequent TiO2 
enrichment and MS analysis confirmed both S688 on MED12 and S749 on MED13 as 
substrates (Fig. 3F and 3G). We did not identify the CCNC site from these experiments 
because the site identified from CA-treated HCT116 cells is not present in the canonical 
CCNC isoform used for recombinant CDK8 module expression and purification.
The data summarized in Figure 3 verified each of seven high-confidence Mediator kinase 
sites, representing about 10% of all high-confidence sites listed in Table 1. These results, 
combined with previous data demonstrating CA potency and specificity (Pelish et al., 2015), 
support the substrates listed in Table 1 as Mediator kinase targets. Although extensive 
kinome profiling has demonstrated CA specificity, we conducted in vitro kinase assays using 
a shared substrate, the pol II CTD, and found that CDK1, ERK2, and GSK3β activity was 
unaffected by CA treatment, even at concentrations ten-fold above those used for proteomic 
and gene expression analyses (Fig. 3H).
Mediator kinase inhibition has limited and specialized effects on transcription
As Mediator-associated kinases, it was plausible that inhibition of CDK8 and CDK19 
activity could affect expression of large numbers of genes. We analyzed gene expression 
(RNA-Seq) data from CA treated HCT116 cells (Table S3). To minimize secondary or 
indirect effects resulting from long-term Mediator kinase inhibition, we completed RNA-Seq 
after a three-hour CA treatment (100 nM); this also helped match mRNA changes with 
measured phosphorylation changes that were determined after one-hour CA treatment. 
RNA-Seq analysis identified 150 genes whose expression changed significantly with CA 
treatment (Fig. 4A). Among these genes, the magnitude of change in expression was modest 
(largely 1.2 – 2 fold), indicating that CDK8/19 activity per se is not a major driver of their 
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transcription, at least in the context of this analysis (HCT116 cells under normal growth 
conditions). Such modest gene expression changes were also observed in CA-sensitive cell 
lines (e.g. MOLM-14), although the genes affected were distinct (Pelish et al., 2015).
Gene expression changes in CA-treated cells compared to CDK8 or CDK19 knockdown
Because CA inhibits both CDK8 and CDK19 kinases, we used previously published 
HCT116 microarray datasets (normal growth conditions), in which either CDK8 or CDK19 
had been stably knocked down (Donner et al., 2010; Galbraith et al., 2013), as a comparison 
to CA-treated HCT116 cells. Only genes exhibiting 1.5-fold change in expression or greater, 
with p-values <0.05, were used from the microarray data; these genes were compared to our 
RNA-seq analysis in which cells were treated with 100 nM CA for three hours. We observed 
only a modest overlap among genes differentially expressed (Fig. 4B; note that because CA 
inhibits both CDK8 and CDK19, gene sets for CDK8 or CDK19 knockdown were 
combined). Because cellular knockdown experiments take over 24 hours to manifest, the 
modest correlation in gene expression changes could reflect the short time of CA treatment. 
However, RNA-seq analyses after 24 hour CA treatment revealed similarly low numbers of 
shared gene expression changes (Fig. 4C). These results, further summarized in Figure S3, 
suggest that the physical presence of the CDK8 or CDK19 protein has distinct effects on 
transcription compared to targeted kinase inhibition.
Functional links between gene expression changes and Mediator kinase substrates
Because many Mediator kinase substrates are transcription factors (Fig. 2A), we 
hypothesized that some of the observed differences in gene expression due to CDK8/19 
inhibition might be caused by changes in TF function. To begin to address this hypothesis, 
we extracted promoter sequences (± 2kb from TSS) for genes that were differentially 
expressed (increased or decreased expression) 3h CA treatment. F-Match was then used to 
compare promoter sequences to controls to determine if any TF binding sites, reported as 
Transfac matrices, were over-represented. The ratio of this increase (CA-treated cells vs. 
DMSO controls) is displayed for over-represented sites in Figure 4D. We found that many 
of the identified Transfac matrices for genes whose expression increased or decreased with 
CA treatment were mutually exclusive (Fig. 4D). That is, an enriched TF binding site in CA 
increased genes was generally not present in CA decreased genes, and vice versa. A 
hypergeometric test confirmed a significant overlap (p-value = 1.15E−5) between Mediator 
kinase targets identified in Table 1 and Transfac matrices identified in our gene expression 
promoter analysis (Fig. S3F).
Many of the Transfac matrices identified by F-match (Fig. 4D) can be traced back to 
Mediator kinase activity, as summarized in Figure S4. For example, the RREB1 TF was 
identified in both the F-match analysis (RREB1_01) and the SILAC phosphoproteomics 
(Table 1). Enriched TF binding sites were observed for genes with altered expression in CA-
treated HCT116 cells (Fig. 4A), including MYC, a β-catenin target gene, EGR1 (i.e. 
KROX_Q6), and HES1, a Notch pathway target gene. Moreover, the MGA and NAB2 
proteins, each high-confidence Mediator kinase substrates, are known regulators of MYC 
and EGR1 activity, respectively (Hurlin et al., 1999; Svaren et al., 1996). Transfac matrices 
representing the AP2 and ATF family of TFs (e.g. AP2alpha_01, ATF1_Q6) were also 
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uncovered in the F-match analysis. The Mediator kinase target KLF12 is a well-established 
repressor of AP2α activity (gene name: TFAP2A) (Imhof et al., 1999), whereas the ATF2 
and ATF7 proteins were each identified as Mediator kinase targets. Finally, enriched binding 
sites for E2F1 and SREBP, previously identified CDK8 kinase substrates (Morris et al., 
2008; Zhao et al., 2012), were found by the F-match analysis shown in Figure 4D. Although 
these TFs were not identified in our HCT116 phosphoproteomics experiments, several co-
regulators of E2F1 or SREBP activity (e.g. MGA, SIRT1; see Discussion) were among the 
high-confidence substrates listed in Table 1. Thus, there are many functional links between 
CA-dependent changes in gene expression (Fig. 4A) and the Mediator kinase targets shown 
in Table 1.
Cellular proteome changes resulting from Mediator kinase inhibition
The ability of CDK8-dependent phosphorylation to regulate protein turnover has been 
reported in both yeast and human cells (Alarcon et al., 2009; Fryer et al., 2004; Nelson et al., 
2003; Raithatha et al., 2012). We therefore hypothesized that CDK8/19 activity might 
modulate protein abundance for some of the substrates identified here. Rather than focus on 
selected Mediator kinase targets, we performed quantitative proteome analyses in CA-
treated cells vs. DMSO controls at six time points (t = 0h, 1h, 3h, 6h, 18h, and 24h). In this 
way, we were able to interrogate many cellular proteins at once, and correlate changes in 
Mediator kinase activity with increased or decreased protein abundance. To complete these 
analyses, we used SILAC labeled HCT116 cells, consistent with the phosphoproteomics 
experiments.
The analysis consisted of a CA treatment time course from 0 to 24 hours, with six time 
points being used in total to treat heavy (Arg10, Lys8) or light (Arg0, Lys0) HCT116 cell 
populations in biological replicate experiments (Fig. 5A, B). Peptides were harvested in a 
manner similar to that used for phosphoproteomics, and 17 fractions from basic reversed-
phase chromatography were analyzed for changes in H/L ratio at each time point. We found 
a high number of overlapping proteins across replicates, and CA treatment did not affect 
global H/L ratios for proteins across the time course in the replicates (Fig. 5B). Given the 
ability of CDK8 to promote substrate turnover in response to specific biological phenomena 
(e.g. starvation) (Nelson et al., 2003; Raithatha et al., 2012), we were somewhat surprised to 
find that CDK8/19 inhibition did not notably alter the abundance of the target proteins listed 
in Table 1, with the exception of MED13 and MED13L. A list of all quantified proteins in 
CA-treated vs. untreated cells (0 – 24h) is provided in Table S4.
An empirical Bayes analysis of the data suggested that most proteome changes occurred at 
either 18 or 24 hours when compared to control (0 hr, in which both populations were 
DMSO treated), as shown by the volcano plot in Fig. 5C. Approximately 200 proteins 
showed significant changes in abundance and these are listed in Table S5 (adj. pval < 0.1). 
To further examine changes in the proteome with CA treatment, gene set enrichment 
analysis (GSEA) was employed (Subramanian et al., 2005). Using the hallmark gene set 
collection, we identified biological processes that displayed significant enrichment scores 
and false discovery rates (Fig. 5D and Table S6). Of these signatures, several have been 
previously shown to be regulated by CDK8, including Wnt/β-catenin signaling, Notch 
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signaling, hypoxia, interferon gamma response, and KRAS signaling (Bancerek et al., 2013; 
Firestein et al., 2008; Fryer et al., 2004; Galbraith et al., 2013; Morris et al., 2008; Xu et al., 
2015). CDK8-dependent transcriptional changes have been implicated in regulation of these 
pathways and therefore, the proteome data corroborate these findings at the protein level. 
The GSEA results also reveal that proteome changes may selectively affect metabolic 
pathways in CA-treated HCT116 cells, with several (e.g. cholesterol homeostasis, fatty acid 
metabolism) previously linked to CDK8 kinase activity in model organisms (Zhao et al., 
2012).
DISCUSSION
The natural product cortistatin A (CA) is an exceptionally selective inhibitor of the Mediator 
kinases CDK8 and CDK19 (Pelish et al., 2015). As such, it provided a means to rapidly and 
selectively probe CDK8 and CDK19-dependent phosphoproteome changes in human cells. 
Because of their association with Mediator, CDK8 and CDK19 were expected to 
phosphorylate proteins involved in regulating pol II activity and chromatin architecture. In 
accordance with these expectations, our data support a primary role for Mediator kinases in 
pol II transcription and chromatin regulation. Strikingly, however, the direct impact of 
Mediator kinase inhibition on global pol II transcription was modest and affected a limited 
set of genes, at least under the conditions of this study. Limited transcriptional effects were 
also observed in CA-sensitive AML cell lines (Pelish et al., 2015).
At the gene expression level, it appears that Mediator kinases predominantly “regulate the 
regulators” of transcription. Many genes whose expression increased or decreased 1.5-fold 
or greater upon CA treatment are DNA-binding TFs or general transcription or chromatin 
regulators. Similarly, DNA-binding TFs and pol II transcription or chromatin regulators 
represented the majority of high-confidence CDK8/CDK19 kinase targets from the SILAC 
phosphoproteomics experiments. Quantitative proteomic data across a 24-hour time course 
implicated numerous signaling and metabolic pathways that appear to be regulated by 
Mediator kinase activity under normal growth conditions. Whereas these pathways can be 
linked to known transcriptional or phosphorylation targets of CDK8/CDK19 or those now 
identified here, much additional investigation will be required to delineate the molecular 
mechanisms by which Mediator kinases regulate specific signaling pathways or 
transcriptional processes.
CDK8/19 phosphorylate Mediator subunits and post-initiation transcription regulators
CDK8 can reversibly associate with Mediator to form a CDK8-Mediator complex (Taatjes et 
al., 2002), and immunoprecipitation-mass spectrometry experiments in HeLa or HEK293T 
cells suggest CDK19 interacts similarly with Mediator (Daniels et al., 2013; Ebmeier and 
Taatjes, 2010; Sato et al., 2004). We identified eight high-confidence CDK8/19 
phosphorylation sites in six different Mediator subunits: CCNC, MED12, MED13, 
MED13L, MED14, and MED26. CCNC, MED12, MED13, and MED13L each associate 
with CDK8 or CDK19 as part of the kinase module of Mediator. MED13 appears to be 
important for physical interaction between the kinase module and Mediator (Knuesel et al., 
2009), and previous studies have shown that increased MED13 or MED13L abundance can 
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increase the proportion of CDK8-Mediator vs. core Mediator in cells (Davis et al., 2013). 
These previous results were shown in the context of inhibition of the E3 ubiquitin ligase 
FBW7, which ubiquitylates MED13 and MED13L to promote their degradation. Our 
quantitative whole proteome data showed that the abundance of MED13 and MED13L were 
each increased in CA-treated HCT116 cells. FBW7-dependent ubiquitylation of MED13 or 
MED13L required prior modification at residue T326, a phospho-degron site in MED13 and 
MED13L (Davis et al., 2013). The CDK8/19 sites identified in MED13 and MED13L are 
distinct (residue S749 and residue S878, respectively) and do not overlap with known or 
predicted phospho-degron motifs; thus, it remains unclear how Mediator kinase activity may 
affect MED13 or MED13L protein levels.
The MED26 subunit is generally absent from CDK8-Mediator purifications (Ebmeier and 
Taatjes, 2010; Sato et al., 2004; Taatjes et al., 2002) and hence, its phosphorylation by 
CDK8 or CDK19 may promote MED26 dissociation from Mediator. The CDK8/19 
modification site on MED26 (S314), however, does not reside in regions required for 
Mediator association (Takahashi et al., 2011). The MED14 subunit is an important 
architectural factor within Mediator, and structural studies with reconstituted partial 
complexes and crosslinking-mass spectrometry (CXMS) revealed MED14 crosslinks with 
several Mediator subunits, including MED8 and MED7, involving MED14 residues 1256 
and 1295, respectively (Cevher et al., 2014). These reside some distance (in sequence space) 
from the Mediator kinase phosphorylation sites (S1112, S1128, S1136). Furthermore, 
CXMS and cryo-EM data with reconstituted yeast Mediator and yeast pol II revealed 
MED14 interactions with pol II and TFIIF (Plaschka et al., 2015). However, the S. cerevisiae 
Med14 subunit from this study consisted of residues 1-755 (of 1082 residues in yeast 
Med14) and the human MED14 S1112, S1128, and S1136 residues do not appear to be 
conserved.
Knockdown experiments have implicated the CDK8 protein in the regulation of transcription 
elongation and/or pol II pausing or pause release (Donner et al., 2010; Galbraith et al., 
2013). Furthermore, ChIP-Seq data from CA-treated MOLM-14 cells indicated a reduced 
pol II travel ratio (TR; ratio of promoter-bound pol II vs. pol II in gene body) at genes whose 
expression was up-regulated by CA (Pelish et al., 2015), implicating Mediator kinase 
activity in pol II pausing or pause release. The reduced TR in CA-treated cells could also 
reflect inhibition of premature pol II termination. Here, we identified AFF4, NELFA, 
MED26, POLR2M, SETX, and XRN2 as high-confidence Mediator kinase targets, and each 
of these factors has been implicated in regulation of pol II pausing, premature termination, 
or elongation (Brannan et al., 2012; Cheng et al., 2012; Jishage et al., 2012; Kwak and Lis, 
2013; Lin et al., 2010; Takahashi et al., 2011; Wagschal et al., 2012).
Mediator kinases as potential metabolic regulators
CDK8 orthologs in Drosophila and yeast have been linked to lipid and glucose metabolism 
and regulation of cellular responses to nutrient stress (Kuchin et al., 1995; Lindsay et al., 
2014; Mousley et al., 2012; Zhao et al., 2012). Upon Mediator kinase inhibition by CA, we 
observed changes in the abundance of about 200 proteins (Fig. 5), including many involved 
in basic metabolic pathways such as oxidative phosphorylation, fatty acid metabolism, and 
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cholesterol homeostasis. MED13 and CCNC appear to regulate mitochondrial function in 
yeast (Cooper et al., 2014; Khakhina et al., 2014), and over-expression of MED13 in mouse 
cardiac tissue alters fatty acid metabolism, β-oxidation, and mitochondrial content (Baskin et 
al., 2014). We identified MED13 and CCNC as Mediator kinase substrates and observed an 
increase in MED13 protein levels upon CA treatment, which could contribute to altered fatty 
acid metabolism or oxidative phosphorylation observed in CA-treated cells (Fig. 5D).
CDK8 kinase activity has previously been linked to cholesterol metabolism and fatty acid 
synthesis via regulation of SREBP. In particular, CDK8-dependent phosphorylation of 
SREBP residue T402 correlated with SREBP degradation in Drosophila and mouse cells 
(Zhao et al., 2012). GSEA analysis of whole proteome data identified changes in the 
cholesterol homeostasis, adipogenesis, and fatty acid metabolism hallmark signatures in CA-
treated cells (Fig. 5D). Moreover, F-match identified SREBP binding motifs as over-
represented among genes whose expression changed upon CA treatment (Fig. 4D). Whereas 
phosphorylation of SREBP T402 was detected in our phosphoproteomics experiments, its 
level was not altered in CA-treated cells, suggesting alternate means of Mediator kinase-
dependent SREBP regulation in HCT116 cells. Other kinases, including GSK3 (Sundqvist et 
al., 2005), are known to target SREBP T402 and we have confirmed that CA does not inhibit 
GSK3β in cell lysates (Pelish et al., 2015) or in in vitro kinase assays with the purified 
protein (Fig. 3H). Therefore, the SREBP T402 phosphorylation level may remain constant 
in CA-treated cells due to other kinases targeting this site. Alternately, SREBP may not be a 
substrate for CDK8 in HCT116 cells. SIRT1, a validated Mediator kinase target, can 
negatively regulate SREBP activity through deacetylation (Walker et al., 2010). The 
Mediator kinases phosphorylate SIRT1 at residue T530, and phosphorylation at T530 has 
been shown to activate the SIRT1 deacetylase (Sasaki et al., 2008). Thus, via SIRT1 and 
potentially other substrates, Mediator kinases may regulate cholesterol or fatty acid 
metabolism independent of direct SREBP phosphorylation in HCT116 cells.
Human Mediator kinases and TF turnover
Previous studies revealed that phosphorylation of nutrient-responsive TFs Gcn4, Ste12, or 
Phd1 by yeast Cdk8 promoted their degradation (Chi et al., 2001; Nelson et al., 2003; 
Raithatha et al., 2012). Studies in metazoans have shown evidence for CDK8-dependent 
phosphorylation of the TFs SMAD1, SMAD3, Notch ICD, SREBP, E2F1, and STAT1 
(Alarcon et al., 2009; Bancerek et al., 2013; Fryer et al., 2004; Morris et al., 2008; Zhao et 
al., 2012). Among these, increased degradation of the Notch ICD, SMAD1, SMAD3, and 
SREBP correlated with phosphorylation. For these reasons, we anticipated that inhibition of 
CDK8 and CDK19 kinase activity would affect the protein levels of a subset of their targets. 
Whole proteome data revealed no evidence that TF phosphorylation by Mediator kinases 
affected their stability, even with analyses at 1, 3, 6, 18, or 24 hours of CA treatment. In fact, 
we found little evidence for altered stability of any high-confidence Mediator kinase targets, 
with the notable exception of MED13 and MED13L. Despite this result, cell type or context 
may be key factors that dictate the effect of Mediator kinase phosphorylation on protein 
turnover. Here, we evaluated HCT116 cells in normal growth conditions whereas Mediator 
kinases may in fact more generally regulate substrate protein turnover during stress 
responses or at different developmental stages.
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Whereas no changes in TF turnover were evident from the whole proteome data in CA-
treated vs. control cells, we identified many links between the gene expression changes and 
the phosphoproteomics data (Fig. S4). These results are consistent with Mediator kinases 
affecting TF activity in HCT116 cells under normal growth conditions, rather than TF 
turnover.
CDK8 as a colon cancer oncogene: Mediator kinase inhibition vs. subunit knockdown
CDK8 was identified as a colon cancer oncogene in part through an shRNA screen for genes 
required for HCT116 cell proliferation (Firestein et al., 2008). CDK8 was one of 166 
candidates in this screen; CDK8 was also identified in a screen for factors required for 
activation of a β-catenin-driven reporter in a different colon cancer line, DLD-1 (Firestein et 
al., 2008). Our analyses with CA indicate that, in contrast to CDK8 knockdown, Mediator 
kinase inhibition does not affect HCT116 cell growth (Pelish et al., 2015). These findings 
highlight the distinction between physical loss of a protein vs. targeted inhibition of its 
enzymatic activity.
As a TF, β-catenin assembles with the DNA-binding proteins TCF and LEF-1 to activate 
genes that drive cell proliferation. HCT116 cells are heterozygous for a mutant β-catenin 
protein that is resistant to degradation (Morin et al., 1997). Consequently, HCT116 cells 
have increased β-catenin levels and are considered “β-catenin-dependent”. Consistent with 
an oncogenic function for CDK8, CDK8 knockdown prevented activation of β-catenin target 
genes in colon cancer cell lines (Firestein et al., 2008). In addition, the E2F1 TF has been 
shown to be an important negative regulator of β-catenin stability (through unknown 
mechanisms), and elevated levels of the CDK8 protein, as observed in HCT116 cells 
(Firestein et al., 2008), can block E2F1-dependent inhibition of β-catenin target gene 
expression (Morris et al., 2008). Thus, in colon cancer cells, the CDK8 protein appears to 
up-regulate β-catenin target gene expression in two ways: as a β-catenin co-activator and as 
an inhibitor of E2F1 activity.
Whereas E2F1 and β-catenin activity or stability is known to be regulated by 
phosphorylation, we did not observe significant changes in E2F1 or β-catenin protein or 
phosphopeptide levels in CA-treated HCT116 cells. An F-match analysis based upon gene 
expression changes in CA-treated cells, however, identified E2F binding motifs as over-
represented (Fig. 4D), and Ingenuity Pathway Analysis (IPA) of upstream regulators 
identified β-catenin target genes as over-represented among those whose expression 
increased or decreased upon CA treatment (Table S7). GSEA of our proteomics data (CA-
treated vs. untreated, 0 – 24h) revealed up-regulation of both the E2F1 and β-catenin 
pathways (Fig. 5D). Furthermore, numerous high-confidence Mediator kinase substrates are 
known to directly regulate β-catenin or E2F activity, and these are summarized in Table S8.
Although these results implicate Mediator kinase activity in the regulation of E2F1 and β-
catenin transcription networks in HCT116 cells, the effects of Mediator kinase inhibition are 
clearly distinct from CDK8 or CDK19 knockdown (Donner et al., 2010; Firestein et al., 
2008; Galbraith et al., 2013). This was not unexpected, as the physical presence of an 
enzyme typically serves structural roles, such as maintaining the integrity of a multi-protein 
complex. For example, ablation of the CDK7 ortholog in yeast (Kin28) abolishes essentially 
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all pol II transcription (Holstege et al., 1998), in contrast to targeted inhibition of Kin28 
activity (Kanin et al., 2007). Direct comparison of the transcriptional changes resulting from 
physical loss of the CDK8 or CDK19 protein versus targeted inhibition of kinase activity 
(i.e. with protein levels remaining intact) revealed stark differences in both the genes 
affected and in the magnitude of gene expression changes. These differences highlight the 
importance of a structural or “scaffolding” role of the CDK8 or CDK19 proteins. Indeed, 
CDK8 knockdown decreases MED12 levels and increases CDK19 protein levels in HCT116 
cells (Donner et al., 2010; Galbraith et al., 2013), which likely contributes to the distinct 
gene expression and anti-proliferative effects of CDK8 knockdown (Firestein et al., 2008) 
compared with kinase inhibition by CA. Because CA inhibits CDK19 as well as CDK8 
(Pelish et al., 2015), this may also result in compensatory effects that distinguish the CDK8 
knockdown phenotype from CDK8/CDK19 inhibition. Future studies are needed to more 
precisely establish the roles of CDK8 vs. CDK19 in regulating the elaborate E2F1, β-
catenin, and other inter-related signaling networks that contribute to HCT116 survival and 
proliferation.
Concluding remarks
This study provides a large-scale identification of Mediator kinase substrates and the impact 
of Mediator kinase activity on pol II transcription and the cellular proteome. In comparison 
with the ~170 potential CDK9 kinase substrates recently identified in HCT116 cells (Sanso 
et al., 2016), it is notable that the high-confidence substrates for CDK9 are distinct from the 
Mediator kinases. This further suggests that CDK9 (e.g. as part of P-TEFb or the SEC) and 
Mediator kinases play non-redundant roles in transcription regulation.
Our results were enabled by the rigorous biochemical, cellular, and biophysical 
characterization of CA, which demonstrated that it represents an unusual case of an inhibitor 
that is truly selective for Mediator kinases in human cells (Pelish et al., 2015). The data and 
methodologies presented provide a valuable resource for further delineation of the molecular 
mechanisms whereby Mediator kinases, and their substrates, regulate processes that are 
fundamentally important in human development and disease. For example, the 
methodologies described could be applied toward other cell types or contexts to uncover cell 
type- or context-specific roles for Mediator kinases. Alternately, the Mediator kinase targets 
or proteome changes identified here could be further tested for their mechanistic role(s) in 
regulating chromatin structure and function, DNA repair or replication, cell metabolism, or 
pol II transcription.
EXPERIMENTAL PROCEDURES
Cell culture
HCT116 cells were cultured in DMEM supplemented with 10% FBS and penicillin/
streptomycin. Cells were maintained at 37°C and 5% CO2.
SILAC labeling
HCT116 cells were cultured in DMEM lacking arginine and lysine (Pierce-88420) 
supplemented with either Arg10 (33.6 μg/ml) and Lys8 (73 μg/ml) or Arg0 and Lys0 for 
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heavy and light treatment, respectively. After six passages at 1:3 ratio, cells were tested for 
Arg/Lys incorporation and were subsequently supplemented with 200mg/L of proline 
(Sigma-P5607) as a small amount of Arg→Pro conversion was detected. Cells were 
maintained in 10% dialyzed FBS and penicillin/streptomycin.
TiO2 phosphopeptide enrichment, ERLIC chromatography, and LC/MS/MS
Protocols were carried out as described (Stuart et al., 2015). An Orbitrap LTQ (Thermo 
Fisher) was used for phosphoproteomics, and an Orbitrap Velos (Thermo Fisher) was used 
for quantitative proteome analysis.
In vitro kinase assays
Assays were done essentially as described (Bancerek et al., 2013). Additional details 
provided in Supplemental Experimental Procedures.
Gene expression comparison between CA treated HCT116 cells and shRNA CDK8/19
shRNA CDK8 and CDK19 microarray data were obtained from the GEO (accession 
GSE38061) and data under the “normoxia” tab were used for the comparison to CA treated 
cells.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Quantitative phosphoproteomics in HCT116 cells ± CA
(A) Cortistatin A (CA) structure.
(B) Overview of phosphoproteomics workflow used to identify Mediator kinase substrates.
(C) Unique phosphopeptides identified with LC-MS/MS after ERLIC fractionation. Average 
of biological triplicates is represented.
(D) CA treatment with quantitative phosphoproteomics reproducibly identifies Mediator 
kinase substrates. H/L ratios quantified in two of three biological replicates are plotted on 
the x- and y- axes. Plot shows proteins whose H/L ratios decrease (green) and increase 
(peach) upon CA treatment.
(E) and (F) Representative mass spectra. Spectra shown are from replicates in which either 
the light (E) or heavy (F) cells were CA-treated. Differences in SILAC pairs are shown 
based on the labeled amino acid; Arg(10) in (E) and Lys(8) in (F). The charge is +2 for both 
peptides.
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Figure 2. Identification of Mediator kinase (CDK8/19) substrates
(A) Functional categorization of high-confidence Mediator kinase substrates identified.
(B) Volcano plot of statistically significant phosphosite changes with CA treatment using an 
empirical Bayes analysis.
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Figure 3. In vitro validation of select CDK8/19 substrates
(A) Validation of STAT1 S727 as a Mediator kinase target in HCT116 cells.
(B) Western blot validation of SIRT1 T530 as a Mediator kinase target. Levels of total 
SIRT1 and other proteins known to regulate CDK8 activity (MED12 or CCNC), remained 
unchanged. TBP is a loading control.
(C) Quantitation of data in (B). Error bars are SEM; n=2 for technical replicates.
(D) In vitro kinase assay with recombinant CDK8 module and SIRT1. With increasing time, 
SIRT1 pT530 detection increases, indicating CDK8 is phosphorylating this site. Increase is 
not seen in no kinase or no substrate (ns) controls.
(E) In vitro kinase assay with GST-tagged TP53BP1 or RIF1 fragments. Alanine mutations 
at identified phosphorylation sites show reduced phosphorylation by CDK8.
(F) Overview of method for identifying MED12 and MED13 phosphorylation sites using 
recombinant CDK8 modules.
(G) Verification of MED12 S688 and MED13 S749 phosphorylation sites.
(H) In vitro kinase assay using CA and GST-pol II CTD as a substrate. Whereas each kinase 
tested phosphorylates this substrate, CA only inhibits the CDK8 module.
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Figure 4. Mediator kinase inhibition is functionally distinct from CDK8 or CDK19 knockdown
(A) Heat map of differentially expressed genes (RNA-Seq) after 3 hr CA treatment. Green 
font represents transcription or chromatin regulator.
(B and C) Comparison with microarray data (Galbraith et al., 2013) using stable CDK8/19 
knockdown (shRNA) vs. 3h CA treatment (B) or 24h treatment (C) in HCT116 cells under 
normal growth conditions. A 1.5-fold cutoff was used for microarray data and Cufflinks was 
used for CA-treated cells (no specific fold-change cutoff).
(D) TFBS analysis of promoters for genes whose expression changed with 3h CA treatment 
(listed in A). Promoters (±2kb from the TSS of the canonical isoform) were analyzed using 
F-Match, part of the Transfac database. Overrepresented sites with at least 1.5 fold increase 
vs. control promoters are shown for Transfac vertebrate matrices. Matrix name at left.
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Figure 5. Quantitative proteomics reveals pathways and proteins affected by Mediator kinase 
inhibition
(A) Overview of quantitative proteomics method.
(B) Venn diagram of biological replicates showing number of proteins identified in the time 
series. Replicates show a high degree of overlap for protein IDs.
(C) Volcano plot comparing protein abundance at 18 hr and 24 hr time points vs. control (0 
hr). Adjusted p-values are colored according to an empirical Bayes analysis.
(D) Individual analysis of t = 3hr, 6hr, 18hr, and 24hr CA treatment time points using GSEA 
and the hallmark gene sets from the Molecular Signatures Database. Comparison of the t = 
0hr and 1hr time points showed no differences in the hallmark gene sets (not shown). The 
color of the heat map corresponds to the direction and magnitude of the normalized 
enrichment score for that gene set at each time point, compared to t = 0hr controls. ‘NA’ and 
the corresponding color indicate a hallmark gene set not being identified from the proteome 
data at the designated time.
(E) Protein abundance increases for MED13 and MED13L in CA-treated cells.
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Table 1
High confidence Mediator kinase substrates identified using CA and quantitative phosphoproteomics
Protein ID Gene Name Position Loc. Prob. Ratio (H/L) Adj. p-value
Q9UHB7 AFF4 S31 0.79 0.209 ± 0.011 0.025
Q9UHB7 AFF4 S32 0.78 0.248 ± 0.070 0.056
Q9UHB7 AFF4 S1043 1.00 0.325 ± 0.035 0.020
Q9UHB7 AFF4 S814 1.00 0.410 ± 0.012 0.018
P15336 ATF2 S136 1.00 0.366 ± 0.012 0.015
P17544 ATF7 S434 0.88 0.302 ± 0.020 0.015
P17544 ATF7 S111 0.75 0.590 ± 0.062 0.082
P17544 ATF7 T112 0.99 0.593 ± 0.019 0.036
O00512 BCL9 S291 0.95 0.694 ± 0.031 0.092
Q12830 BPTF S1300 1.00 0.691 ± 0.035 0.095
P38398 BRCA1 S1613 0.96 0.447 ± 0.036 0.025
Q9H8M2 BRD9 S588 1.00 0.455 ± 0.009 0.019
H0YBQ5;E5RFK5 CCNC;CCNC S218;S272 1.00 0.642 ± 0.037 0.066
Q12873 CHD3 S1601 1.00 0.595 ± 0.036 0.048
Q14839 CHD4 T1553 0.94 0.096 ± 0.002 0.018
Q9P2D1 CHD7 T2153 0.99 0.572 ± 0.024 0.034
K4DI93 CUL4B S15 0.90 0.394 ± 0.038 0.078
Q9UER7 DAXX S671 1.00 0.651 ± 0.014 0.053
Q5T1V6 DDX59 S64 / S76 0.99 / 0.76 0.535 ± 0.045 0.064
Q9NPF5 DMAP1 T409 1.00 0.134 ± 0.018 0.015
P19419 ELK1 S324 1.00 0.636 ± 0.058 0.092
Q52LR7 EPC2 T353 0.97 0.403 ± 0.019 0.059
Q96E09 FAM122A S267 0.79 0.513 ± 0.082 0.085
Q12948 FOXC1 S241 1.00 0.433 ± 0.063 0.048
Q9NZM4 GLTSCR1 S755 1.00 0.394 ± 0.052 0.032
P15822 HIVEP1 S479 0.99 0.649 ± 0.019 0.055
Q7Z6Z7 HUWE1 S3816 0.98 0.527 ± 0.018 0.025
Q8NFU5 IPMK S7 1.00 0.663 ± 0.050 0.098
Q9Y4C1 KDM3A S445 1.00 0.448 ± 0.034 0.025
Q9Y4X4 KLF12 S202 1.00 0.441 ± 0.071 0.056
Q3ZCW2 LGALSL S25 0.99 0.698 ± 0.029 0.092
Q92585 MAML1 S159 1.00 0.325 ± 0.009 0.015
Q92585 MAML1 S303 0.98 0.356 ± 0.018 0.049
Q14676 MDC1 S1775 1.00 0.453 ± 0.075 0.061
Q93074 MED12 S688 0.99 0.168 ± 0.036 0.020
Q9UHV7 MED13 S749 0.96 0.356 ± 0.041 0.073
Q71F56 MED13L S878 1.00 0.568 ± 0.060 0.065
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Protein ID Gene Name Position Loc. Prob. Ratio (H/L) Adj. p-value
O60244 MED14 S1112 1.00 0.233 ± 0.045 0.025
O60244 MED14 S1128 / S1136 0.99 / 0.99 0.100 ± 0.015 0.025
O95402 MED26 S314 1.00 0.177 ± 0.039 0.025
Q8IWI9 MGA S2924 0.99 0.660 ± 0.032 0.070
O14686 MLL2 S3199 0.98 0.630 ± 0.019 0.047
P55197 MLLT10 S346 1.00 0.470 ± 0.005 0.076
O96007 MOCS2 S20 1.00 0.531 ± 0.035 0.034
Q9NV56 MRGBP S195 1.00 0.611 ± 0.023 0.043
Q6P1R3 MSANTD2 S27 1.00 0.623 ± 0.053 0.085
Q2TAK8 MUM1 S326 1.00 0.582 ± 0.050 0.059
Q15742 NAB2 S162 1.00 0.573 ± 0.014 0.032
Q15788 NCOA1 S698 1.00 0.381 ± 0.042 0.081
Q9H3P2 NELFA S363 0.96 0.403 ± 0.032 0.023
Q9H3P2 NELFA S360 0.50 0.441 ± 0.039 0.092
Q6P4R8 NFRKB S1291 1.00 0.688 ± 0.035 0.092
Q9NZT2 OGFR S349 1.00 0.170 ± 0.015 0.025
Q9NZT2 OGFR S484 0.99 0.348 ± 0.035 0.021
P29590 PML S530 1.00 0.674 ± 0.012 0.059
Q6EEV4 POLR2M S10 0.99 0.416 ± 0.018 0.019
Q5UIP0 RIF1 S1613 0.98 0.357 ± 0.014 0.048
Q5UIP0 RIF1 S1616 1.00 0.418 ± 0.051 0.033
Q92766 RREB1 S1653 1.00 0.237 ± 0.025 0.039
Q6SPF0 SAMD1 S425 0.94 0.418 ± 0.022 0.019
O15047 SETD1A T1088 1.00 0.204 ± 0.010 0.015
Q7Z333 SETX S2612 1.00 0.465 ± 0.018 0.080
Q96EB6 SIRT1 T530 1.00 0.201 ± 0.030 0.043
Q9UQ35 SRRM2 S2449 1.00 0.708 ± 0.004 0.081
P42224 STAT1 S727 0.99 0.367 ± 0.001 0.047
Q12962 TAF10 S44 1.00 0.565 ± 0.020 0.032
Q7Z2Z1 TICRR S1413 0.99 0.472 ± 0.066 0.059
Q12888 TP53BP1 S265 1.00 0.258 ± 0.014 0.015
Q12888 TP53BP1 S525 1.00 0.600 ± 0.014 0.036
P13051 UNG S63 0.84 0.473 ± 0.026 0.025
P13051 UNG T60 / S63 0.99 / 0.62 0.487 ± 0.027 0.025
Q9H0D6 XRN2 S487 1.00 0.566 ± 0.041 0.047
Q9NUA8 ZBTB40 T166 0.99 0.378 ± 0.078 0.058
A6NFI3 ZNF316 S10 1.00 0.598 ± 0.043 0.056
Q6ZN55 ZNF574 S717 1.00 0.406 ± 0.052 0.033
O15014 ZNF609 S804 1.00 0.373 ± 0.001 0.015
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All sites correspond to reviewed accessions and canonical isoforms in Uniprot except for CCNC, whose identified site is not present in the 
canonical isoform. The ‘p-value’ column represents an adjusted p-value from an empirical Bayes analysis (Ritchie et al., 2015). See also 
Supplemental Note.
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